Accéder au contenu
Merck

Barium sulfate suspension as a negative oral MRI contrast agent: in vitro and human optimization studies.

Magnetic resonance imaging (1991-01-01)
K C Li, R P Tart, J R Fitzsimmons, B L Storm, J Mao, R J Rolfes
RÉSUMÉ

In vitro proton spectroscopy with line-width measurements and MR imaging were performed on various concentrations of commercially available single contrast (SC), double contrast, oral and rectal barium sulfate suspensions, as well as potassium sulfate, barium chloride, barium hydroxide, and 97% pure barium sulfate suspensions. Approximately 500 ml of 20%, 40%, 60%, and 70% w/w suspensions of SC oral barium sulfate suspensions were administered to four normal volunteers, respectively, and MR images were obtained at both 1.5 T and 0.15 T. Subsequently, 500 ml of 60% w/w suspensions of SC oral barium sulfate suspensions were administered to five normal volunteers and imaged at 1.5 T. All of the inert suspensions produced line-width broadening but the SC oral barium sulfate suspension at 50% and 70% stayed in suspension even after hours of standing undisturbed. As much as 80% of the small bowel and the entire colon were well visualized using the combination of 60% or 70% w/w SC barium sulfate suspensions with SE 550/22 and FISP pulse sequences. The effect was less at 0.15 T and also with the SE 2000/45/90 pulse sequences. We conclude that barium sulfate suspensions are useful as oral MRI contrast agents.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Barium hydroxide octahydrate, ACS reagent, ≥98%
Sigma-Aldrich
Barium hydroxide, technical grade, ~95%
Sigma-Aldrich
Barium hydroxide octahydrate, ≥98%
Sigma-Aldrich
Barium hydroxide monohydrate, 98%
Sigma-Aldrich
Barium hydroxide solution, 0.3 N